Pacira Stock Based Compensation vs Begin Period Cash Flow Analysis

PCRX Stock

USD 18.40 0.07 0.38%

Pacira BioSciences, financial indicator trend analysis is much more than just breaking down Pacira BioSciences, prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacira BioSciences, is a good investment. Please check the relationship between Pacira BioSciences, Stock Based Compensation and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira BioSciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacira BioSciences, Stock Based Compensation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Pacira BioSciences,'s Stock Based Compensation and Begin Period Cash Flow is 0.45. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Pacira BioSciences,, assuming nothing else is changed. The correlation between historical values of Pacira BioSciences,'s Stock Based Compensation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Pacira BioSciences, are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Pacira BioSciences,'s Stock Based Compensation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Pacira BioSciences,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacira BioSciences, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira BioSciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.At this time, Pacira BioSciences,'s Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 2.8 M in 2025, whereas Enterprise Value Over EBITDA is likely to drop 13.81 in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	40.0M	20.3M	23.4M	15.8M
Depreciation And Amortization	91.5M	75.6M	86.9M	91.3M

Interest Expense Depreciation And Amortization

Pacira BioSciences, fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.84	0.61	0.97	0.78	0.99	0.46	0.95	0.43	0.63	0.62	0.98	0.84	0.45	0.97	0.74	0.97	0.61	0.68	0.32	0.98	0.95	0.86	0.83	0.97	0.93
Other Current Liab	0.84		0.82	0.73	0.82	0.82	0.3	0.79	0.18	0.51	0.77	0.77	0.85	0.68	0.79	0.9	0.72	0.66	0.69	0.41	0.8	0.73	0.65	0.83	0.89	0.64
Total Current Liabilities	0.61	0.82		0.42	0.76	0.55	0.1	0.51	0.05	0.1	0.89	0.52	0.78	0.65	0.5	0.78	0.43	0.41	0.39	0.15	0.54	0.47	0.51	0.49	0.74	0.35
Total Stockholder Equity	0.97	0.73	0.42		0.65	0.98	0.49	0.91	0.49	0.65	0.45	0.97	0.77	0.34	0.93	0.61	0.99	0.59	0.69	0.34	0.94	0.97	0.83	0.81	0.88	0.99
Other Liab	0.78	0.82	0.76	0.65		0.72	0.09	0.68	0.39	0.5	0.87	0.76	0.7	0.35	0.76	0.69	0.7	0.37	0.44	-0.06	0.78	0.68	0.72	0.64	0.86	0.61
Property Plant And Equipment Net	0.99	0.82	0.55	0.98	0.72		0.49	0.95	0.39	0.64	0.53	0.97	0.82	0.46	0.96	0.71	0.97	0.65	0.73	0.39	0.96	0.97	0.84	0.85	0.94	0.94
Current Deferred Revenue	0.46	0.3	0.1	0.49	0.09	0.49		0.52	-0.06	0.51	0.02	0.39	0.41	0.36	0.48	0.52	0.43	0.41	0.4	0.69	0.48	0.45	0.25	0.52	0.41	0.44
Net Debt	0.95	0.79	0.51	0.91	0.68	0.95	0.52		0.39	0.64	0.45	0.94	0.8	0.55	0.97	0.71	0.91	0.59	0.63	0.42	0.97	0.87	0.76	0.81	0.93	0.86
Retained Earnings	0.43	0.18	0.05	0.49	0.39	0.39	-0.06	0.39		0.18	0.11	0.55	0.4	0.1	0.39	-0.11	0.48	-0.25	-0.12	-0.39	0.41	0.39	0.47	0.04	0.34	0.53
Accounts Payable	0.63	0.51	0.1	0.65	0.5	0.64	0.51	0.64	0.18		0.21	0.6	0.34	0.13	0.69	0.51	0.65	0.4	0.52	0.45	0.68	0.66	0.37	0.73	0.57	0.62
Cash	0.62	0.77	0.89	0.45	0.87	0.53	0.02	0.45	0.11	0.21		0.55	0.65	0.35	0.55	0.73	0.49	0.41	0.42	-0.05	0.57	0.52	0.62	0.51	0.74	0.4
Non Current Assets Total	0.98	0.77	0.52	0.97	0.76	0.97	0.39	0.94	0.55	0.6	0.55		0.79	0.38	0.96	0.61	0.98	0.54	0.63	0.2	0.97	0.95	0.86	0.77	0.93	0.95
Non Currrent Assets Other	0.84	0.85	0.78	0.77	0.7	0.82	0.41	0.8	0.4	0.34	0.65	0.79		0.74	0.74	0.79	0.72	0.46	0.49	0.38	0.77	0.71	0.74	0.66	0.86	0.72
Other Assets	0.45	0.68	0.65	0.34	0.35	0.46	0.36	0.55	0.1	0.13	0.35	0.38	0.74		0.39	0.66	0.26	0.31	0.25	0.56	0.41	0.27	0.25	0.42	0.53	0.21
Long Term Debt	0.97	0.79	0.5	0.93	0.76	0.96	0.48	0.97	0.39	0.69	0.55	0.96	0.74	0.39		0.71	0.94	0.59	0.65	0.32	1.0	0.91	0.83	0.82	0.95	0.89
Cash And Short Term Investments	0.74	0.9	0.78	0.61	0.69	0.71	0.52	0.71	-0.11	0.51	0.73	0.61	0.79	0.66	0.71		0.58	0.66	0.63	0.61	0.72	0.62	0.56	0.79	0.82	0.52
Net Receivables	0.97	0.72	0.43	0.99	0.7	0.97	0.43	0.91	0.48	0.65	0.49	0.98	0.72	0.26	0.94	0.58		0.58	0.69	0.24	0.95	0.98	0.84	0.8	0.89	0.98
Common Stock Total Equity	0.61	0.66	0.41	0.59	0.37	0.65	0.41	0.59	-0.25	0.4	0.41	0.54	0.46	0.31	0.59	0.66	0.58		0.97	0.55	0.58	0.64	0.51	0.88	0.59	0.55
Common Stock Shares Outstanding	0.68	0.69	0.39	0.69	0.44	0.73	0.4	0.63	-0.12	0.52	0.42	0.63	0.49	0.25	0.65	0.63	0.69	0.97		0.5	0.64	0.75	0.58	0.92	0.63	0.66
Short Term Investments	0.32	0.41	0.15	0.34	-0.06	0.39	0.69	0.42	-0.39	0.45	-0.05	0.2	0.38	0.56	0.32	0.61	0.24	0.55	0.5		0.31	0.31	0.03	0.57	0.29	0.25
Non Current Liabilities Total	0.98	0.8	0.54	0.94	0.78	0.96	0.48	0.97	0.41	0.68	0.57	0.97	0.77	0.41	1.0	0.72	0.95	0.58	0.64	0.31		0.91	0.84	0.81	0.96	0.89
Inventory	0.95	0.73	0.47	0.97	0.68	0.97	0.45	0.87	0.39	0.66	0.52	0.95	0.71	0.27	0.91	0.62	0.98	0.64	0.75	0.31	0.91		0.82	0.83	0.87	0.96
Other Current Assets	0.86	0.65	0.51	0.83	0.72	0.84	0.25	0.76	0.47	0.37	0.62	0.86	0.74	0.25	0.83	0.56	0.84	0.51	0.58	0.03	0.84	0.82		0.64	0.83	0.84
Other Stockholder Equity	0.83	0.83	0.49	0.81	0.64	0.85	0.52	0.81	0.04	0.73	0.51	0.77	0.66	0.42	0.82	0.79	0.8	0.88	0.92	0.57	0.81	0.83	0.64		0.8	0.76
Total Liab	0.97	0.89	0.74	0.88	0.86	0.94	0.41	0.93	0.34	0.57	0.74	0.93	0.86	0.53	0.95	0.82	0.89	0.59	0.63	0.29	0.96	0.87	0.83	0.8		0.82
Property Plant And Equipment Gross	0.93	0.64	0.35	0.99	0.61	0.94	0.44	0.86	0.53	0.62	0.4	0.95	0.72	0.21	0.89	0.52	0.98	0.55	0.66	0.25	0.89	0.96	0.84	0.76	0.82

Click cells to compare fundamentals

Pacira BioSciences, Account Relationship Matchups

Pacira BioSciences, fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.3B	2.1B	1.7B	1.6B	1.8B	1.9B
Other Current Liab	85.7M	127.6M	80.7M	64.2M	73.9M	41.2M
Total Current Liabilities	253.3M	521.1M	147.8M	97.4M	112.0M	123.5M
Total Stockholder Equity	619.7M	730.4M	775.0M	870.1M	1.0B	1.1B
Other Liab	21.5M	17.4M	77.6M	37.8M	43.5M	24.9M
Property Plant And Equipment Net	211.2M	264.8M	254.4M	234.9M	270.2M	283.7M
Net Debt	441.2M	543.3M	659.3M	432.7M	497.7M	522.5M
Retained Earnings	(253.9M)	(211.9M)	(148.8M)	(106.8M)	(96.1M)	(100.9M)
Accounts Payable	10.4M	10.5M	15.2M	15.7M	18.1M	10.4M
Cash	100.0M	585.6M	104.1M	153.3M	176.3M	117.4M
Non Current Assets Total	622.9M	1.2B	1.2B	1.1B	1.2B	1.3B
Non Currrent Assets Other	74.5M	76.4M	27.2M	36.0M	41.5M	43.5M
Other Assets	290.1M	153.4M	160.3M	1.0	1.15	1.09
Long Term Debt	313.0M	674.5M	655.8M	513.8M	590.9M	620.4M
Cash And Short Term Investments	521.7M	656.4M	288.7M	278.6M	320.4M	237.8M
Net Receivables	53.0M	96.3M	98.4M	105.6M	121.4M	127.5M
Common Stock Shares Outstanding	43.7M	45.6M	46.5M	52.0M	59.8M	35.9M
Short Term Investments	421.7M	70.8M	184.5M	125.3M	144.1M	137.9M
Liabilities And Stockholders Equity	1.3B	2.1B	1.7B	1.6B	1.8B	1.9B
Non Current Liabilities Total	401.5M	823.8M	758.4M	606.9M	697.9M	732.8M
Inventory	64.7M	98.6M	96.1M	104.4M	120.0M	126.0M
Other Current Assets	12.3M	29.4M	15.2M	21.5M	24.7M	26.0M
Other Stockholder Equity	873.2M	942.1M	924.1M	976.6M	1.1B	599.8M
Total Liab	654.8M	1.3B	906.2M	704.3M	809.9M	850.4M
Property Plant And Equipment Gross	211.2M	264.8M	254.4M	370.3M	425.8M	447.1M
Total Current Assets	651.6M	866.0M	498.3M	510.0M	586.5M	331.8M
Accumulated Other Comprehensive Income	318K	167K	(380K)	247K	284.1K	298.3K
Short Term Debt	157.1M	382.6M	51.9M	17.4M	20.1M	19.1M
Intangible Assets	96.5M	624.0M	540.5M	483.3M	555.7M	583.5M
Common Stock	42K	44K	45K	46K	52.9K	35.1K
Property Plant Equipment	104.7M	136.7M	264.8M	254.4M	292.5M	307.2M
Short Long Term Debt Total	541.1M	1.1B	763.4M	586.0M	674.0M	348.5M
Net Tangible Assets	151.0M	423.6M	(38.7M)	71.2M	81.9M	77.8M
Retained Earnings Total Equity	(388.2M)	(399.4M)	(253.9M)	(211.9M)	(190.7M)	(200.2M)
Capital Surpluse	709.7M	754.0M	873.2M	942.1M	1.1B	685.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Stock Based Compensation vs Begin Period Cash Flow Analysis

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Begin Period Cash Flow

Pacira BioSciences, fundamental ratios Correlations

Pacira BioSciences, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacira BioSciences, fundamental ratios Accounts

Also Currently Popular

Additional Tools for Pacira Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Long Term Debt
Property Plant And Equipment Net	+ 0.99	Total Assets
Net Receivables	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Total Assets

Short Term Investments	- 0.39	Retained Earnings
Common Stock Total Equity	- 0.25	Retained Earnings
Common Stock Shares Outstanding	- 0.12	Retained Earnings
Cash And Short Term Investments	- 0.11	Retained Earnings
Retained Earnings	- 0.06	Current Deferred Revenue
Short Term Investments	- 0.06	Other Liab